Antibodies to oxidized low-density lipoprotein in patients following coronary artery revascularization

Coronary Artery Disease

Volumn 14, Issue 2, 2003, Pages 163-169

  Miller III, Edgar R ^a,b   Erlinger, Thomas P ^a,b   Blumenthal, Roger S ^a   Margolis, Simeon ^a   Allen, Jerilyn K ^a,c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

Antibodies to oxidized LDL; Clinical trial; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANTIBODY; ANTIOXIDANT; C REACTIVE PROTEIN; CAROTENOID; ISOPROSTANE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; OXYGEN RADICAL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NURSING; OXIDATIVE STRESS; PATIENT CARE; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

AGED; ANTIBODIES; ANTILIPEMIC AGENTS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; OXIDATION-REDUCTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REACTIVE OXYGEN SPECIES; STATISTICS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0038408567     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200304000-00009     Document Type: Article

References (37)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase atherogenicity. N Eng J Med 1989; 320:915-924.
2. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344:793-795.
3. Horkko S, Binder CJ, Shaw PX, Chang M, Silverman G, Palinski W, et al. Immunological responses to oxidized LDL. Free Radic Biol Med 2000; 28:1771-1779.
4. Shaw PX, Horkko S, Tsimikas S, Chang M, Palinski W, Silverman GJ, et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol 2001; 21:1333-1339.
5. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995; 92:821-825.
6. Freigang S, Horkko S, Miller E, Witztum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998; 18:1972-1982.
7. Wu JT, Wu LL. Autoantibodies against oxidized LDL: a potential marker for atherosclerosis. Clin Lab Med 1997; 17:595-604.
8. Inoue T, Uchida T, Kamishirado H, Takayanagi K, Hayashi T, Morooka S. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol 2001; 37:775-779.
9. Puurunen M, Manttari M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154:2605-2609.
10. Lehtimaki T, Lehtinen S, Solakivi T, Nikkila M, Jaakkola O, Jokela H, et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol. 1999; 19:23-27.
11. Yasunobu Y, Hayashi K, Shingu T, Yamagata T, Kajiyama G, Kambe M. Coronary atherosclerosis and oxidative stress as reflected by autoantibodies against oxidized low-density lipoprotein and oxysterols. Atherosclerosis 2001; 155:445-453.
12. Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Circulation 1994; 15:441-445.
13. Salonen JT, Nyyssonen K, Salonen R, Porkkala-Sarataho E, Tuomainen T-P, Diczfalusy U, et al. Lipoprotein oxidation and progression of carotid atherosclerosis. Circulation 1997; 95:840-845.
14. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339:883-887.
15. Holvoet P, Mertens A, Verhamme P, Gogaerts K, Beyens G, Verhaeghe R, et al. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Atheroscl Thromb Vasc Biol 2001; 21:844-848.
16. Allen JK, Blumenthal RS, Margolis S, Young DR, Miller ER III, Kelly K. Case Management of hypercholesterolemia compared with enhanced usual care in patient with coronary heart disease. Am Heart J 2002; 144:678-686.
17. Bachorik PS, Cloey TA, Finney CA, Lowery DL, Becker DM. Lipoprotein-cholesterol analysis during screening: accuracy and reliability. Ann Intern Med 1991; 114:741-747.
18. Bachorik PS, Ross JW. National cholesterol program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995; 41:1414-1420.
19. Friedwald WT, Levy RI, Friedrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparitive ultracentrifugation. Clin Chem 1972; 18:499-502.
20. Cao G, Alessio HM, Cutler RG. Oxygen-radical absorbance capacity assay for antioxidants. Free Radic Biol Med 1993; 14:303-311.
21. Craft NE. High resolution HPLC method for the simultaneous analysis of caretenoids, retinoids and tocopherols. FASEB J 1996; 10:1A527.
22. Orem C, Orem A, Uydu HA, Celik S, Erdol C, Kural BV. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status. Coron Artery Dis 2002; 13:65-71.
23. Hoogerbrugge N, Kerkhofs LGM, Jansen H. Gemfibrozil decreases autoantibodies against oxidized low-density lipoprotein in men with combined hyperlipidaemia. J Intern Med 1998; 243:355-359.
24. Inoue T, Hayashi M, Takayanagi K, Morooka S. Lipid-lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hyperdholesterolemic patients. Atherosclerosis 2002; 160:369-376.
25. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. JAMA 1998; 279:1643-1650.
26. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97:1440-1445.
27. Vasankari T, Ahotupa M, Toikka J, Mikkola J, Irjala K, Pasanen P, et al. Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy. Atherosclerosis 2001; 155:403-412.
28. Miller ER III, Appel LJ, Risby TH. The effects of dietary patterns on measures of lipid peroxidation: results from a randomized clinical trial. Circulation 1998; 98:2390-2395.
29. Cao G, Sofic E, Prior RL. Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Free Radic Biol Med 1997; 22:749-760.
30. Rubba P, Panico S, Gond G, Covetti G, Celentano E, Iannuzzi A, et al. Site-specific atherosclerotic plaques in the carotid arteries of middle-aged women from southern Italy. Stroke 2001; 32:1953-1959.
31. Meraviglia MV, Maggi E, Bellomo G, Cursi M, Fanelli G, Minicucci F. Autoantibodies against oxidatively modified lipoproteins and progression of carotid restenosis after carotid endarterectomy. Stroke 2002; 33:1139-1141.
32. Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J, Kanda H, et al. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000; 148:171-177.
33. Wu R, Faire U, Lemne C, Witztum JL, Frostegard J. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 1999; 33:53-59.
34. Fukumoto M, Shoji T, Emoto M, Kawagishi T, Okuno Y, Nishizawa Y. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 2000; 20:703-707.
35. Lopes-Virella M, Virella G, Orchard TJ, Koskinen S, Evans RW, Becker DJ, et al. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus. Clin Immun 1999; 90:165-172.
36. Korpinen E, Groop P, Akerblom H, Vaarala O. Immune response to glycated and oxidized LDL in IDDM patients with and without renal disease. Diabetes Care 1997; 20:1168-1171.
37. Festa A, Kopp HP, Schernthaner G, Menzel EJ. Autoantibodies to oxidized low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia 1998; 41:350-356.